Risks for secondary solid tumors after Hodgkin's disease treatment according to primary site.
| Tumor Site . | Observed/Expected . | Relative Risk . | 95% Confidence Intervals . | Absolute Risk* . |
|---|---|---|---|---|
| Lung/pleura | 36 / 3.5 | 10.3 | 7.0 - 13.7 | 16.2 |
| Breast | 25 / 6.1 | 4.1 | 2.4 - 5.7 | 21.5 |
| Melanoma | 9 / 0.8 | 11.6 | 5.7 - 21.3 | 4.1 |
| Soft tissue (sarcoma) | 8 / 0.3 | 24.3 | 11.3 - 48.3 | 3.8 |
| Bone (osteosarcoma) | 2 / 0.2 | 12.3 | 2.1 - 41.6 | 0.9 |
| Stomach | 8 / 1.6 | 4.9 | 2.3 - 9.4 | 3.2 |
| Salivary gland | 5 / 0.1 | 37.9 | 13.8 - 84.2 | 2.4 |
| Thyroid | 5 / 0.5 | 10.6 | 3.9 - 23.6 | 2.3 |
| Urogenital sites§ | 15 / 6.8 | 2.2 | 1.3 - 2.9 | 4.1 |
| Pancreas | 3 / 0.8 | 3.9 | 1.0 - 10.5 | — |
| Colon or rectum | 6 / 4.7 | 1.3 | 0.5 - 2.7 | — |
| Unknown primary | 3 / 0.9 | 3.4 | 0.8 - 9.2 | — |
| Oral cavity | 1 / 1.5 | 0.7 | 0.0 - 3.3 | — |
| Tumor Site . | Observed/Expected . | Relative Risk . | 95% Confidence Intervals . | Absolute Risk* . |
|---|---|---|---|---|
| Lung/pleura | 36 / 3.5 | 10.3 | 7.0 - 13.7 | 16.2 |
| Breast | 25 / 6.1 | 4.1 | 2.4 - 5.7 | 21.5 |
| Melanoma | 9 / 0.8 | 11.6 | 5.7 - 21.3 | 4.1 |
| Soft tissue (sarcoma) | 8 / 0.3 | 24.3 | 11.3 - 48.3 | 3.8 |
| Bone (osteosarcoma) | 2 / 0.2 | 12.3 | 2.1 - 41.6 | 0.9 |
| Stomach | 8 / 1.6 | 4.9 | 2.3 - 9.4 | 3.2 |
| Salivary gland | 5 / 0.1 | 37.9 | 13.8 - 84.2 | 2.4 |
| Thyroid | 5 / 0.5 | 10.6 | 3.9 - 23.6 | 2.3 |
| Urogenital sites§ | 15 / 6.8 | 2.2 | 1.3 - 2.9 | 4.1 |
| Pancreas | 3 / 0.8 | 3.9 | 1.0 - 10.5 | — |
| Colon or rectum | 6 / 4.7 | 1.3 | 0.5 - 2.7 | — |
| Unknown primary | 3 / 0.9 | 3.4 | 0.8 - 9.2 | — |
| Oral cavity | 1 / 1.5 | 0.7 | 0.0 - 3.3 | — |
Absolute risk is the excess number of observed cancers per 10,000 patients per year according to the formula:
Absolute risk = [(observed - expected) / person-years] × 10,000.
Absolute risks are not specified when 95% confidence intervals for relative risk include 1.0.
Urogenital tumors included cancers of the endometrium (3), cervix (2), ovary (2), vulva (1), prostate (3), testis (1), kidney (2) and bladder (1). Relative risks were not significantly elevated for any specific urogenital tumor site.